What is the share price of Aspira Pathlab & Diagnostics Ltd (ASPIRA) today?
The share price of ASPIRA as on 16th May 2025 is ₹53.25. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Aspira Pathlab & Diagnostics Ltd (ASPIRA) share?
The past returns of Aspira Pathlab & Diagnostics Ltd (ASPIRA) share are- Past 1 week: -5.30%
- Past 1 month: -1.34%
- Past 3 months: -17.63%
- Past 6 months: -23.82%
- Past 1 year: 66.20%
- Past 3 years: -6.58%
- Past 5 years: 45.89%
What are the peers or stocks similar to Aspira Pathlab & Diagnostics Ltd (ASPIRA)?
The peers or stocks similar to Aspira Pathlab & Diagnostics Ltd (ASPIRA) include:What is the market cap of Aspira Pathlab & Diagnostics Ltd (ASPIRA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aspira Pathlab & Diagnostics Ltd (ASPIRA) is ₹54.81 Cr as of 16th May 2025.What is the 52 week high and low of Aspira Pathlab & Diagnostics Ltd (ASPIRA) share?
The 52-week high of Aspira Pathlab & Diagnostics Ltd (ASPIRA) is ₹106.78 and the 52-week low is ₹25.What is the PE and PB ratio of Aspira Pathlab & Diagnostics Ltd (ASPIRA) stock?
The P/E (price-to-earnings) ratio of Aspira Pathlab & Diagnostics Ltd (ASPIRA) is 27.00. The P/B (price-to-book) ratio is 4.89.Which sector does Aspira Pathlab & Diagnostics Ltd (ASPIRA) belong to?
Aspira Pathlab & Diagnostics Ltd (ASPIRA) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Aspira Pathlab & Diagnostics Ltd (ASPIRA) shares?
You can directly buy Aspira Pathlab & Diagnostics Ltd (ASPIRA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Aspira Pathlab & Diagnostics Ltd
ASPIRA Share Price
53.255.00% (-2.80)
ASPIRA Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
ASPIRA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.13 | 4.89 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.21 | 6.44 | 0.55% |
ASPIRA Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ASPIRA Company Profile
Aspira Pathlab & Diagnostics Limited is an India-based company engaged in diagnostic centre and laboratories related business. The Company operates Pathology labs and diagnostics centers across India.
ASPIRA Similar Stocks (Peers)
Compare with peersMAXHEALTH
PE Ratio
107.28
1Y Return
37.46%
Buy Reco %
75.00
APOLLOHOSP
PE Ratio
112.25
1Y Return
18.26%
Buy Reco %
86.21
FORTIS
PE Ratio
88.25
1Y Return
55.97%
Buy Reco %
100.00
PE Ratio
45.67
1Y Return
40.69%
Buy Reco %
66.67
MEDANTA
PE Ratio
67.03
1Y Return
13.90%
Buy Reco %
71.43
ASPIRA Forecasts
Price
Revenue
Earnings
ASPIRA Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeASPIRA Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeASPIRA Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeASPIRA
Income
Balance Sheet
Cash Flow
Annual Normal View
ASPIRA Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.07 | 4.58 | 7.89 | 8.71 | 15.41 | 19.63 | 14.78 | 13.62 | 22.39 | 22.45 | ||||||||||
Raw Materials | 0.14 | 1.30 | 2.26 | 1.99 | 2.63 | 3.14 | 2.50 | 2.62 | 18.87 | 18.93 | ||||||||||
| Power & Fuel Cost | 0.12 | 0.42 | 0.49 | 0.32 | 0.13 | 0.21 | 0.24 | 0.26 | ||||||||||||
| Employee Cost | 1.61 | 3.42 | 4.47 | 4.95 | 4.03 | 5.02 | 5.59 | 6.20 | ||||||||||||
| Selling & Administrative Expenses | 1.39 | 2.61 | 2.64 | 1.92 | 2.16 | 2.94 | 2.59 | 2.59 | ||||||||||||
| Operating & Other expenses | 0.07 | 0.48 | 1.03 | 1.07 | 2.74 | 1.86 | 1.95 | 2.72 | ||||||||||||
EBITDA | -2.26 | -3.65 | -3.00 | -1.54 | 3.72 | 6.46 | 1.91 | -0.77 | 3.52 | 3.52 | ||||||||||
| Depreciation/Amortization | 0.20 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 | 1.50 | ||||||||||
| PBIT | -2.46 | -4.77 | -4.23 | -3.20 | 2.28 | 4.82 | 0.32 | -2.31 | 2.03 | 2.02 | ||||||||||
| Interest & Other Items | 0.26 | 0.80 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.00 | — | ||||||||||
| PBT | -2.72 | -5.57 | -5.19 | -4.21 | 1.39 | 4.45 | -0.10 | -2.68 | 2.03 | 2.02 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | -2.72 | -5.57 | -5.19 | -4.24 | 1.39 | 4.45 | -0.10 | -2.68 | 2.03 | 2.02 | ||||||||||
| EPS | -7.31 | -10.73 | -7.75 | -4.85 | 1.42 | 4.32 | -0.10 | -2.60 | 1.97 | 1.96 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
ASPIRA Company Updates
FY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFASPIRA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareHospitals & Diagnostic Centres
Compare valuation on Screener
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Aspira Pathlab & Diagnostics Ltd | 27.00 | 4.89 | — |
| Max Healthcare Institute Ltd | 107.28 | 13.49 | 0.13% |
| Apollo Hospitals Enterprise Ltd | 112.25 | 13.78 | 0.23% |
| Fortis Healthcare Ltd | 88.25 | 6.18 | 0.14% |
ASPIRA Stock Price Comparison
Compare ASPIRA with any stock or ETFCompare ASPIRA with any stock or ETF
ASPIRA
ASPIRA Shareholdings
ASPIRA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ASPIRA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ASPIRA Shareholding Pattern
ASPIRA Shareholding History
Foreign Institutions
smallcases containing ASPIRA stock
Looks like this stock is not in any smallcase yet.
ASPIRA Events
ASPIRA Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASPIRA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ASPIRA Dividends
Hmm, looks like data is unavailable here. Please come back after some timeASPIRA Stock News & Opinions
Articles & Videos
Earnings
Aspira Pathlab & Diagnostics reports consolidated net profit of Rs 0.68 crore in the March 2025 quarter
Net profit of Aspira Pathlab & Diagnostics reported to Rs 0.68 crore in the quarter ended March 2025 as against net loss of Rs 0.50 crore during the previous quarter ended March 2024. Sales rose 51.31% to Rs 5.78 crore in the quarter ended March 2025 as against Rs 3.82 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 2.02 crore in the year ended March 2025 as against net loss of Rs 2.67 crore during the previous year ended March 2024. Sales rose 66.67% to Rs 22.00 crore in the year ended March 2025 as against Rs 13.20 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales5.783.82 51 22.0013.20 67 OPM %15.92-5.50 -14.23-11.74 - PBDT1.05-0.13 LP 3.52-1.13 LP PBT0.68-0.50 LP 2.02-2.67 LP NP0.68-0.50 LP 2.02-2.67 LP Powered by Capital Market - Live
16 hours agoCapital Market - Live
Corporate
Aspira Pathlab & Diagnostics to declare Quarterly Results
Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 16 May 2025.Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Aspira Pathlab & Diagnostics reports standalone net profit of Rs 0.38 crore in the December 2024 quarter
Net profit of Aspira Pathlab & Diagnostics reported to Rs 0.38 crore in the quarter ended December 2024 as against net loss of Rs 0.74 crore during the previous quarter ended December 2023. Sales rose 56.36% to Rs 5.41 crore in the quarter ended December 2024 as against Rs 3.46 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales5.413.46 56 OPM %14.23-10.69 - PBDT0.77-0.36 LP PBT0.38-0.74 LP NP0.38-0.74 LP Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Aspira Pathlab & Diagnostics to table results
Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 7 February 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Aspira Pathlab & Diagnostics reports standalone net profit of Rs 0.99 crore in the September 2024 quarter
Net profit of Aspira Pathlab & Diagnostics reported to Rs 0.99 crore in the quarter ended September 2024 as against net loss of Rs 0.71 crore during the previous quarter ended September 2023. Sales rose 86.14% to Rs 6.18 crore in the quarter ended September 2024 as against Rs 3.32 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales6.183.32 86 OPM %21.84-10.84 - PBDT1.35-0.32 LP PBT0.99-0.71 LP NP0.99-0.71 LP Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Aspira Pathlab & Diagnostics schedules board meeting
Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Aspira Pathlab & Diagnostics AGM scheduled
Aspira Pathlab & Diagnostics announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Aspira Pathlab & Diagnostics reports standalone net loss of Rs 0.02 crore in the June 2024 quarter
Net Loss of Aspira Pathlab & Diagnostics reported to Rs 0.02 crore in the quarter ended June 2024 as against net loss of Rs 0.72 crore during the previous quarter ended June 2023. Sales rose 78.46% to Rs 4.64 crore in the quarter ended June 2024 as against Rs 2.60 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales4.642.60 78 OPM %7.54-12.69 - PBDT0.36-0.33 LP PBT-0.02-0.72 97 NP-0.02-0.72 97 Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Aspira Pathlab & Diagnostics to announce Quarterly Result
Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Aspira Pathlabs shares rise amidst Q1 results; promoters mull increasing stake in co
1 year agoThe Hindu Businessline
Over the last 5 years, revenue has grown at a yearly rate of 11.54%, vs industry avg of 10.01%
Over the last 5 years, market share stayed at 0.02%